Drug Development, Immuno-oncology, Insiders

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

George Yancopoulos doesn’t think very highly of the competition Regeneron {$REGN} faces in the frenzied scramble for a major share of the PD-1/L1 market.

During a fairly brief sit-down at JPMorgan, the Regeneron R&D chief ridiculed Pfizer’s choice for checkpoint partnering, said market leader Merck was now being forced to play catch-up on Regeneron’s first approved indication for their checkpoint Libtayo (cemiplimab) and slammed the use of PD-L1s in general — one of two targets used to release an immune system attack on cancer cells — as “medical malpractice.”

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 37,400+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->